This summary is generated by an algorithm. If you find any mistakes, let us know.

Biopharma Biotechnology Health Care North America Pharmaceutical

Credence MedSystems Raises $39.9M in Funding

– Credence MedSystems, a Menlo Park, CA-based provider of drug delivery systems, raised $39.9M in funding.
– The round was led by Novartis Pharma AG and Molex Ventures LLC.
– The investment will be directed towards scaling of production capacity for the Credence Companion® and Dual Chamber Reconstitution Systems as well as development of other members of the company’s platform of innovative drug delivery systems, including its connected health portfolio.

Source
Biopharma Biotechnology North America Therapeutics

Elevian Raises $40M Series A

– Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, has raised $40m in an oversubscribed Series A round.
– The round was led by Prime Movers Lab.
– Additional investors include Bold Capital, Leslie Ventures, John A Kuelbs Family Office and others.

Source
Biopharma Biotechnology Health Care Medical North America

Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures

– Aptinyx Inc. has entered into a $50m loan facility and security agreement with K2 HealthVentures.
– The funds will provide general growth capital as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators.
– Under the terms of the agreement, the remaining $25m is subject to the achievement of certain terms and conditions, including regulatory and developmental milestones.

Source
Biopharma Biotechnology Therapeutics Western Europe

TreeFrog Therapeutics Raises $75M In Series B Financing

– TreeFrog Therapeutics, a Bordeaux, France-based biotech startup focused on developing stem cell-derived cell therapies for millions of patients, closed a $75m (€64M) Series B financing round, bringing the total funding to date to $83m (€70m).
– The round was led by Bpifrance Large Venture, part of the French Public Investment Bank, joined by U.S. investment firm Leonard Green & Partners L.P., global pharmaceutical company Bristol Myers Squibb, and European venture capital team XAnge.
– The company intends to use the funds to deploy biomimetic C-StemTM technology for clinical-grade manufacturing, grow and advance to the clinic a comprehensive pipeline of cell therapies, and finance the opening of technological hubs in Boston, MA, and Kobe, Japan.

Source
Biopharma Biotechnology GreenTech Manufacturing North America

Solugen Raises Over $350 Million in Series C Funding Led by Baillie Gifford & GIC to Make Carbon Negative Chemicals

– Solugen, the company decarbonizing the chemicals industry, announced a Series C financing round of over $350m.
GIC and Baillie Gifford led the round with participation from Temasek Holdings.
– The latest round of funding will be used to expand Solugen’s Bioforge technology platform, which is used to produce lower-carbon and carbon-negative chemicals & materials for its key customers, and to expand the reach of Solugen’s product portfolio.

Source
Biopharma Health Care Medical North America Pharmaceutical

ARS Pharmaceuticals Raises $55M in Series D Funding

– ARS Pharmaceuticals, a San Diego CA-based pharmaceutical company, raised $55M in Series D funding.
– The round was led by SR One with participation from RA Capital Management and Deerfield Management.
– The company intends to use the funds to advance Neffy through approval, to support initial launch activities, and to evaluate it in clinical studies for additional indications.

Source
Biopharma Biotechnology Pharmaceutical Western Europe

Cardior Raises €64M in Series B Funding

– Cardior Pharmaceuticals from Hanover develops non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases.
– The company closed a €64m ($76m) Series B financing round.
– The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds.
– The new investment will be used for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline.

Source
Biopharma Biotechnology Health Care Medical Western Europe

SolasCure Raises UK£1.2M in Funding

– SolasCure is a biotech startup that develops wound cleaning products.
– The company raised £1.2m in funding.
Seneca Partners invested in the round.
– The company intends to use the funds for the further development of its wound cleaning product, Aurase®.

Source
Biopharma Health Care Medical Device North America

Neuspera Medical Closes $65M Series C Equity Financing

– Neuspera Medical Inc. closed a $65m series C equity financing.
– The round was co-led by Vertex Ventures HC and Treo Ventures with participation from returning Series A and Series B investors Action Potential Venture Capital and Windham Venture Partners.
– The new funding will be used to conduct the SANS-UUI pivotal clinical study of its miniaturized implantable neuromodulation technology platform for use in subjects with Urinary Urgency Incontinence, a symptom of overactive bladder (OAB).

Source
Biopharma Biotechnology Life Science North America

Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept

– Giiant Pharma inc. announced that is closed an additional financing of $750,000 from AQC Capital and $500,000 from CQDM for a total of $1.25 million.
– The preclinical-stage biotech Company’s also closed a Seed round of $13.5 million, co-led by Amplitude Ventures and Genesys Capital.
– This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.
– Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. The team is also in active discussions with potential partners to expand its pipeline of precisely delivered drug therapeutics for gastrointestinal disease.

Source
Biopharma Biotechnology Life Science North America

Eikonoklastes Closes Series A Funding

– Eikonoklastes Therapeutics from Cincinnati, Ohio develops immunotherapies to treat a broad range of cancers beginning with Triple Negative Breast Cancer (TNBC), a lethal form of breast cancer that comprises 15% of all breast cancers.
– The company raised an undisclosed amount in Series A funding.
– The round was led by CincyTech with participation from New York-based Elk Capital Ventures, Jobs Ohio, Rev1, and other undisclosed investors.
– The new investment will be used to conduct Investigational New Drug (IND) enabling studies for Eikonoklastes Therapeutics’ L-ICON3 immune conjugate platform.

Source
Bioinformatics Biopharma Biotechnology North America

TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases

– TRexBio, a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, announced the successful close of the final tranche of a $59m Series A financing.
– Proceeds from the financing will be used to expand the company’s unique discovery platform that maps human tissue regulatory T cell (Treg) behavior to dysregulation in disease, and to advance its six preclinical therapeutic programs.
– Investors include Eli Lilly and Company, SV Health, Johnson & Johnson Innovation, Pfizer Ventures, and Alexandria Venture Investments.
– TRexBio also announced the appointment of Johnston Erwin as Chief Executive Officer, and Ovid Trifan, M.D., Ph.D., as Chief Medical Officer, as part of the company’s plan to accelerate growth.

Source
Biopharma Biotechnology Medical Pharmaceutical Southeast Asia

Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies

– Nuevocor has announced the completion of an oversubscribed $24m Series A financing round.
– The round was co-led by EVX Ventures and Boehringer Ingelheim Venture Fund (BIVF), with EDBI, Xora Innovation, SEEDS Capital and other investors joining the syndicate.
– Funds will be used to accelerate the preclinical development of its lead programme, an adeno-associated virus (AAV) – based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the lamin A/C (LMNA) gene.

Source
Biopharma Biotechnology Developer Platform Information Technology North America

Umoja Biopharma Raises $210M in Series B Funding

– Umoja Biopharma is a Seattle, WA-based oncology company.
– The company closed a $210m Series B financing.
– The round was co-led by SoftBank Vision Fund 2 and Cormorant Asset Management with participation from new investors, including RTW Investments, LP; Temasek; Presight Capital (the international venture arm of Christian Angermayer’s Apeiron Investment Group); Caas Capital; and an investment fund associated with SVB Leerink.

Source
Biopharma Biotechnology Developer Platform Information Technology North America

Immunotherapy startup Umoja lands $210M, less than a year after raising $53M

– Umoja Biopharma, a Seattle-based immunotherapy company, raised $210m in Series B funding.
– The round was led by SoftBank Vision Fund 2 and Cormorant Asset Management.
– New investors included RTW Investments, LP, Temasek, Presight Capital, Caas Capital and SVB Leerink.
– Funds also came from existing investors: MPM Capital, DCVC Bio, Qiming Venture Partners USA, Casdin Capital, The Emerson Collective and Alexandria Venture Investments.

Source
Biopharma Biotechnology Health Care Therapeutics Western Europe

Ochre Bio Closes $9.6M Seed Financing Led by Khosla Ventures

– Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced the closing of a $9.6M seed financing round led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxton and Hermes-Epitek.
– The funding will be used to advance the development of Ochre Bio’s RNA therapies and expand their deep phenotyping platform to identify and validate new liver targets.
– Using deep phenotyping (‘phenomics’), the company digitizes liver biology at scale, from healthy through to advanced liver disease.
– Ochre Bio has already generated massive amounts of spatial genomics data from freshly donated human livers, and have uncovered hundreds of novel potential liver targets that are currently being validated in their labs.

Source
Biopharma Biotechnology North America Therapeutics

CAMP4 Raises $45 Million to Usher in a New Era of Programmable Therapeutics to Upregulate Genes

– CAMP4 Therapeutics announced that it has raised $45m to propel the next phase of its scientific strategy, significantly expand its platform and advance multiple preclinical RNA therapies into human testing.
– CAMP4 is combining its proprietary RNA Actuating Platform (RAP) with state-of-the-art oligonucleotide technology to develop precise and programmable therapeutics that enable tunable upregulation of gene expression to treat disease.
– CAMP4’s approach uniquely targets a new class of RNA known as regulatory RNAs (“regRNAs”) that control the expression of proteins, making this approach applicable to any genetic disease whereby a small increase in gene output can lead to meaningful therapeutic outcomes.
5AM Ventures and Northpond Ventures led the financing alongside existing investors Andreessen Horowitz, Polaris Partners and The Kraft Group.

Source
Biopharma Biotechnology Pharmaceutical Therapeutics Western Europe

HiFiBiO Therapeutics Closes $75M Series D

– HiFiBiO Therapeutics, a biotechnology company with expertise in immune modulation and drug intelligent science, announced the completion of an oversubscribed $75M Series D financing round.
– The funding was led by the new investor Mirae Asset Financial Group.
B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund also participated in this round.

Source
Biopharma Biotechnology North America Pharmaceutical

Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway

– Onchilles Pharma announced a $7m Series A financing from LYZZ Capital and includes a $500k investment from the University of Chicago’s Startup Investment Fund.
– The proceeds of the financing will be used to develop first-in-class therapeutics to activate a novel pathway of the innate immune system with potential for universal anti-cancer activity, independent of genetic mutation.
– Research published in today’s issue of Cell is the first to describe this pathway where human neutrophils release catalytically active neutrophil elastase, called ELANE, to selectively kill many cancer cell types while sparing non-cancer cells.
– ELANE is an entirely new treatment paradigm with the potential to have broad and selective cancer killing activity regardless of genetic mutation or anatomical origin.

Source
Biopharma Biotechnology Therapeutics Western Europe

Iksuda Therapeutics Closes $47 Million Financing Round

– Iksuda Therapeutics (Iksuda) has completed a US $47m financing round.
– The round was co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners.
– Iksuda’s lead pre-clinical candidate, IKS03, is a best-in-class CD19-targeted ADC candidate for B-cell cancers.
– The investment will enable progression of IKS03 to first-in-human phase 1 clinical trials.
– It will also be used to accelerate the Company’s earlier-stage programmes including IKS04 and IKS012 to IND filing.
– Iksuda’s ADC programmes target tumours that currently have limited treatment options and high relapse rates.

Source
Biopharma Biotechnology Mechanical Engineering Pharmaceutical Western Europe

RheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV

– RheaVita, a company pioneering continuous freeze-drying technology for biopharmaceutical products, announced that the company has closed a EUR 2.5 million Series A Financing.
– The round was co-led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV).
– Concurrent with the financing, Kjell Mortier from Novalis Biotech Acceleration and Stefan De Waele of PMV will join RheaVita’s Board of Directors.
– RheaVita has developed the world’s first end-to-end continuous freeze-drying solution to address biopharmaceutical product development, manufacturing and supply needs in order to efficiently reach patients.
– The patented RheaVita continuous freeze-drying technology integrates all the traditional freeze-drying process steps into one continuous production line.

Source
Biopharma Biotechnology Health Care North America

miRecule Closes $5.7M Funding Round

– miRecule, Inc. from Gaithersburg MD develops RNA therapeutics to treat a range of diseases including cancer, muscular dystrophy, and even viruses such as HIV and COVID-19.
– Series A $5.7m funding will be used to bring its lead microRNA therapy (MC-30) to clinical development for head & neck cancer.
– The round was led by Alexandria Venture Investments, with participation from Boutique Venture Partners, Pathway Bioventures, Alumni Ventures Group, and national angel investors.

Source
Biopharma Biotechnology Medical North America

Oisín Biotechnologies Raises Seed Funding to Advance Therapies for Age-Related Diseases

– Oisín Biotechnologies has completed an oversubscribed round raising $5m in new seed funding.
– The round was led by early-stage investing firm Althea Group, LLC.
– Oisín’s highly precise, DNA-based interventions are designed to clear senescent cells, which can trigger aging pathologies and shorten lifespan, from the body.
– Oisín expects the first readouts from its preclinical study in CKD, OB-001, later this year.

Source
Biopharma Biotechnology Health Care Medical Western Europe

HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs

– HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18 million seed round.
– The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.
– Founded and led by a team of experts in lncRNA biology and fibrotic disease, HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.

Source
Biopharma Biotechnology Health Diagnostics Life Science Medical Therapeutics Western Europe

Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

– Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing.
– The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.

Source
Biopharma Biotechnology Health Care North America Pharmaceutical Therapeutics

Interius BioTherapeutics Raises $76M in Series A Financing

– Interius BioTherapeutics, a Philadelphia, PA-based preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, raised $76m in Series A financing.
– The round was co-led by Cormorant Asset Management and Fairmount Funds, and joined by Bain Capital Life Sciences, Pfizer Ventures, RA Capital Management, Longwood Fund, Logos Capital, Osage University Partners and Quan Capital.

Source
Biopharma Biotechnology North America Pharmaceutical Therapeutics

Sparrow Pharmaceuticals Secures $50 Million Series A Financing

– Sparrow Pharmaceuticals closed a $50m Series A financing.
– The financing was led by OrbiMed with participation from RiverVest Venture Partners and U.S. Venture Partners (USVP).
– This financing will allow the company to accelerate the development of its proprietary oral HSD-1 inhibitor, SPI-62, which targets the source of steroids that cause toxicity in key tissues.
– Sparrow also announced the appointment of biopharmaceutical industry veteran Robert Jacks as President and Chief Executive Officer.
– Sparrow was founded by Dr. David Katz, Chief Scientific Officer of Sparrow, to leverage underappreciated insights in corticosteroid biology.

Source
Biopharma Biotechnology Health Care Medical North America

Peroxitech Therapeutics Secures Seed Financing to Advance New Treatment of Acute Lung Injury

– Peroxitech Therapeutics, Inc. announced their launch with a seed investment from Xontogeny to advance their lead program through completion of IND-enabling work.
– Peroxitech’s lead product, PIP-2 is delivered into the lungs to prevent the cytokine storm cascade to treat and prevent ALI.
– PIP-2 helps to target cytokine build up in the lungs that leads to respiratory failure with hypoxemia and tissue acidosis, regardless of etiology.
Xontogeny will provide Peroxitech with the expertise and resources to advance their lead program through completion of IND-enabling work.

Source
Biopharma Biotechnology North America Pharmaceutical

NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease

– NephroDI Therapeutics, Inc. announced a seed investment from Xontogeny, LLC to advance their lead program through critical preclinical work.
– X-linked NDI affects 1 in 250,000 males in the US and is characterized by profoundly excessive urination of up to 20L (5 gal) per day and frequent complications.
– NephroDI’s lead product, NDI-5033 is a unique AMPK activator that can stimulate water reabsorption without causing hypoglycemia, decreasing overall urine output.
– NDI-5033 is being developed for the congenital form of NDI.
– Current management measures are minimally effective and onerous in that they require patients to drink as much fluid as they excrete to prevent dehydration and eat an extremely restricted diet.

Source
Biopharma Biotechnology North America Pharmaceutical

Ultivue Announces $50M Financing Round

– Ultivue announced the completion of a $50m Series D round of financing.
– New investors include Ally Bridge Group, Pura Vida Investments and Tao Capital Partners.
– Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC.
– This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows.

Source
Biopharma Health Care North America Pharmaceutical

Arcellx Raises $115M in Series C Financing

– Arcellx Raises $115M in Series C Financing.
– The round was co-led by Samsara BioCapital and CAM Capital, joined by new investors Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital (a Citadel company), Suvretta, and Terra Magnum Capital Partners.
– The new investment will be used to develop CART-ddBCMA and initiate clinical trials evaluating ACLX-001 and ACLX-002 in multiple myeloma (MM) and acute myelogenous leukemia (AML) respectively.

Source
Biopharma Biotechnology Health Care Medical North America Pharmaceutical

Precision Medicine Company adyn Raises $2.5M Seed Funding for Personalized Birth Control

– adyn, a precision medicine company, announced today that it has closed a $2.5m seed round of funding.
– The round was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, Ascend VC, and angel investors including Anne Wojcicki of 23andMe, Nish Bhat of Color Genomics, Qasar Younis of Applied Intuition, and Ashley Mayer of Glossier.
– adyn uses proprietary hormone and genomic analyses to transform this selection process into a science and remove the guesswork.
– Using adyn’s precision medicine approach, patients and doctors will be able to personalize birth control selection, minimizing side effects ranging from annoyances like acne to life threatening conditions including blood clots and depression.

Source
Biopharma Europe Health Care Pharmaceutical

Maxwellia Raises £3.2M in Funding

– Maxwellia is an Alderley Park, UK-based self-care company.
– The company raised £3.2m in funding led by Praetura Ventures with participation from the Future Fund, Catapult Ventures, Alderley Park Ventures and Biocity along with individual and angel investors.
– The new investment will be used to scale up the manufacture and rollout of drugs following MHRA approval.
– Maxwellia’s chief executive Anna Maxwell is a pharmacist with over 20 years’ experience.

Source
Biopharma Biotechnology North America Therapeutics

Antios Therapeutics Raises $96M in a Series B

– Antios Therapeutics from San Diego, CA announced the successful completion of a $96m Series B financing.
– The financing was led by Soleus Capital with participation from new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as other healthcare focused funds, Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participation from all of the original Series A investors including Lumira Ventures, CAM Capital, Delos Capital, Domain Associates and Sixty Degree Capital.
– Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.

Biopharma Biotechnology Life Science North America

Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem

– Alloy Therapeutics announced a $75m Series C financing round.
– The round was led by 8VC, Presight Capital, and Peter Thiel with participation from new investors including Mubadala Capital, the asset management arm of Mubadala Investment Company.
– Proceeds will extend Alloy’s platforms and services into adjacent biologic modalities and further expand access to Alloy’s capabilities to more partners and geographies around the world.
– Fabian Hansen, founder and Managing Director of US venture capital fund Presight Capital, will join as a member of Alloy Therapeutics’ board of directors.
– Alaa Halawa, co-head of Mubadala Capital’s US Ventures business, will join as a board observer.

Source
Biopharma Biotechnology Health Care Medical North America Therapeutics

Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors

– Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints today announced the closing of a $73 million Series B1 and B2 financing.
– The round was led by Oceanpine Capital with participation from additional new investors including Octagon Capital and Sphera Healthcare, and existing investors, including Northern Light Venture Capital and Vivo Capital.
– In conjunction with this round of financing, Oceanpine CEO and managing partner Dave Chenn joins the Immune-Onc Board of Directors.

Source
Asia Biopharma Biotechnology Clinical Trials Innovation Management

Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies

– Bioheng Biotech raised $80m in Series B financing.
– The round was led by GL Ventures, the venture capital unit of Hillhouse Capital, Decheng Capital and Octagon Capital, with the participation of BlueRun Ventures and Shenzhen Capital Group Company.
– Proceeds will be used to advance R&D capabilities, process development and clinical trials.
– Bioheng is dedicated on developing novel cellular immunotherapy for cancer.

Source
Biopharma Biotechnology Europe Health Care

PhoreMost Raises $46M in Series B Financing

– PhoreMost is a Cambridge, England, UK-based biopharmaceutical company.
– The company raised $46m in Series B funding.
– The round was led by BGF, and included new investor – XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures.
– Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.

Source
Asia Biopharma Biotechnology Health Care Therapeutics

EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and Broaden Clinical Pipeline

– EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibody development, announced today the closing of a $120m Series C financing round.
– The round was co-led by China Merchants Bank International (CMBI) and Mirae Asset Financial Group (Mirae), and joined by Hony Capital, Cormorant Asset Management, Yanchuang Capital, Octagon Capital, renowned cultural entrepreneur and investor Adrian Cheng and ShangBay Capital, with strong participation from existing investors such as Decheng Capital, SDIC Fund, Sherpa Healthcare Partners, and Hidragon Capital.
– Proceeds from the financing will be used to fund the ongoing clinical development of EMB-01, EMB-02 and EMB-06, and to expand the company’s pipeline of novel bispecific antibodies and other biologics.

Source
Biopharma Biotechnology Clinical Trials Life Science North America Pharmaceutical

UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments

– UroGen Pharma Ltd. (Nasdaq: URGN) entered into a strategic funding agreement with RTW Investments, LP and its affiliated entities (“RTW”).
– Under the terms of the agreement, subject to customary closing conditions, UroGen will receive $75m in upfront cash from RTW in return for tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto® (mitomycin) for pyelocalyceal solution as well as UGN-102, if approved.

Source
Biopharma Medical North America

Curi Bio Raises $6M Series A Financing Round for iPSC-derived Predictive Platforms

– Curi Bio Raises $6M Series A Financing Round for iPSC-derived Predictive Platforms
– The round was led by Dynamk Capital
– The investment will be used to scale its existing business and accelerate the development of new innovative human stem cell platforms, including its MantarrayTM platform.
– With this financing round, Curi Bio is welcoming Dr. Gustavo Mahler, Managing Partner at Dynamk Capital, as a new board member.

Source
Biopharma Biotechnology Europe

Amphista Therapeutics Raises $53M in Series B Funding

– Amphista Therapeutics from Glasgow, Scotland, UK, raised $53m in Series B funding.
– The round was co-led by Forbion and Gilde Healthcare with participation from Novartis Venture Fund, and Eli Lilly and Company, and existing investor BioMotiv and founding investor Advent Life Sciences.
– The new investment will be used to accelerate the company’s pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.

Source
Artificial Intelligence Biopharma Health Care Health Diagnostics North America Software

Paige Secures Financing from KKR for Total Series C Funding Round of Over $125 Million

– Paige, a global leader in AI-based diagnostic software in pathology, today announced that KKR, a leading global investment firm, joined Casdin Capital and Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as co-leads in its Series C financing round, bringing the round to over $125 million.
– Paige will use this new capital to expand its geographic footprint as it accelerates the development of AI-based clinical applications, biomarkers and diagnostics.
– Additional investors in the Series C round include Catalio Capital Management, existing investors and other funds, as previously announced.
– For KKR, the investment is being funded through the firm’s Health Care Strategic Growth Fund, which is focused on investing in high-growth health care-related companies for which KKR can be a unique partner in helping reach scale.

Source
Biopharma Biotechnology Health Care North America Therapeutics

Bionaut Labs Emerges From Stealth With $20M

– Bionaut Labs, a company focused on Revolutionizing the treatment of central nervous system disorders (CNS) with its Bionaut™ precision medicine treatment modality, today announced its launch backed by $20m financing led by Khosla Ventures.
– Other investors in the syndicate included Upfront Ventures, Revolution, BOLD Capital, and Compound.
– Proceeds from the financing support the advancement of the Company’s lead therapeutic program in glioma through preclinical development.

Source
Biopharma Biotechnology North America Therapeutics

Kizoo Provides Seed Funding for Elastrin Therapeutics to Develop Groundbreaking New Technology Capable of Reversing Tissue and Organ Calcification

– Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.
– It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level.
– Elastrin’s lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the treatment of heart valve and vascular calcification.
– The Elastrin team has developed a platform that can restore vascular health by removing pathological calcification specifically from sites where elastin has been degraded.

Source
Biopharma North America Pharmaceutical Therapeutics

BlossomHill Therapeutics Inks $71M Series A

– BlossomHill Therapeutics, a biopharmaceutical company focusing on oncology and autoimmune disorders, has raised $71m in a Series A financing round.
Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads.
– In conjunction with the financing, Bihua Chen of Cormorant Asset Management, George J. Lee, Ph.D., of Hercules BioVentures Partners, and Carl L Gordon, Ph.D., CFA, of OrbiMed Advisors joined the company’s Board of Directors.

Source
Biopharma Biotechnology Europe Health Care Life Science Medical Medical Device

CN Bio Awarded Innovate UK Grant to Develop Single and Multi-organ Models for COVID-19 Research

– CN Bio announced a grant from Innovate UK to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection.
– The funding will be used to develop and test advanced cell culture models that represent different regions of the lung and subsequently linking these models to other organ systems, such as liver and gut, to inform the rapid development of novel therapeutics.
– The fast-moving nature of the COVID-19 pandemic directs additional pressure onto current drug discovery and development processes, which can be limited by misrepresentative in vivo models that cause a large proportion of new medicines to fail when taken to clinical trials.
– To circumvent this, CN Bio is developing single and multi-organ COVID-19 models to investigate virology and immunology throughout the body, with a prolonged viable cell culture time for extended studies.

Source
Biopharma Biotechnology Health Care North America Therapeutics

Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease

– Tenaya Therapeutics secured $106m in Series C funding.
– The round was led by RTW Investments, LP and adds new investors RA Capital Management, Fidelity Management & Research Company and funds and accounts advised by T. Rowe Price Associates, Inc.
– The new funding will allow Tenaya to advance its lead gene therapy program towards clinical studies; progress new programs towards IND-enabling studies; build on existing drug discovery and development capabilities across its three platforms; and invest in cGMP manufacturing capabilities.

Source
Biopharma Biotechnology Life Science Machine Learning Manufacturing North America

AbSci Announces Strategic Investment

– AbSci announced a strategic equity investment by Merck Global Health Innovation Fund.
– Merck GHI is a fund of Merck Research Laboratories.
– AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that reinvents the biopharmaceutical drug discovery process.

Source
Biometrics Biopharma Biotechnology North America

ABclonal Biotechnology Completes $93 Million Series C Financing

– ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital.
– Other new and existing shareholders, such as Sigma Square Capital, Kinghall Ventures, and Lucion Capital, participated in the new round.
– ABclonal Biotechnology, parent company of Massachusetts-based life science research and diagnostic reagents manufacturer, ABclonal Technology, will use the additional funding to accelerate the company’s research and development pipeline for in vitro diagnostic raw materials and rapidly expand production capabilities of its research reagent products and services.
– ABclonal is also currently in talks to acquire a contract research organization focused on single-cell-based monoclonal antibody development. This will be the company’s first step toward using the $92.

Source
Biopharma Biotechnology Europe Therapeutics

EMERCell Receives Strategic Investment from Onward Therapeutics

Onward Therapeutics from Montpellier, France, invested in EMERCell.
– The amount of the deal was not disclosed.
– EMERCell SAS is a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
Onward Therapeutics became the majority shareholder after it invested in EMERCell SAS.

Source
Biopharma Biotechnology Developer Tools Europe Health Care

GeneQuine Biotherapeutics Raises Over Euro 9M in Series A and Non-Dilutive Funding

– GeneQuine is a Hamburg, Germany-based biotech company focused on the development of gene therapy for musculoskeletal disorders.
– The company raised a total of €9.05m in Series A and non-dilutive funding.
– The round was led by Pacira BioSciences, Inc. (Nasdaq: PCRX), with participation from High-Tech Gründerfonds, Noshaq SA, and Samum Vermögensverwaltungs GmbH.

Source
Biopharma Biotechnology North America Therapeutics

Sagimet Biosciences Raises $80M in Crossover Financing

– Sagimet Biosciences, a San Mateo, Calif.-based clinical-stage biotechnology company, raised $80m in crossover financing.
– The round was led by an undisclosed public equity healthcare investment fund with participation from existing investors (including Ascletis, Kleiner Perkins, New Enterprise Associates (NEA) and Rock Springs Capital) along with new investors (Altium Capital, HM Capital, Invus and PFM Health Sciences).
– The company intends to use the funds to advance its lead program, TVB-2640 for NASH, to explore additional indications, to file an IND on a second FASN inhibitor, TVB-3567, by the end of 2021.

Source
Biopharma Biotechnology Health Care Medical North America Pharmaceutical

Day One Biopharmaceuticals Inks $130M Series B Financing

– Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating therapies for children and adults with cancer, announced a $130 million Series B financing.
– The financing was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors. Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.

Source
Biopharma Biotechnology Health Care Medical North America Pharmaceutical

Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children

– Day One Biopharmaceuticals announced a $130m Series B financing round bringing total investment in the company to $190m.
– The round was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., and Viking Global Investors.
– Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.
– Proceeds from the Series B financing will allow Day One to accelerate and expand its search and evaluation capabilities, support drug development efforts and continue advancing commercial launch plans for the Company’s lead program, DAY101.

Source
Biopharma Biotechnology Health Care North America Pharmaceutical Therapeutics

ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing

– ImmunoMet Therapeutics received IND clearance and orphan drug designation from the U.S. FDA for IM156 in idiopathic pulmonary fibrosis (IPF).
– The Company also announced the closing of $7.0M in new financing by both existing and new investors that will be used, in part, to fund the Phase 1 program.
– The Company plans to initiate a single-site U.S. Phase 1 study in 32 healthy volunteers designed to characterize the safety, tolerability, pharmacokinetics, and effects of IM156 in Q1 2021.
– Data from this Phase 1 study will inform the design of a Phase 2 trial in patients with IPF.

Source
Crunchbase icon

Content report

The following text will be sent to our editors: